Beam Therapeutics Inc
$ 28.96
-7.00%
02 Jun - close price
- Market Cap 2,989,660,000 USD
- Current Price $ 28.96
- High / Low $ 30.48 / 28.80
- Stock P/E N/A
- Book Value 11.71
- EPS -0.49
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.06 %
- 52 Week High 36.44
- 52 Week Low 15.60
About
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$51.07
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.91 | 2.33 | -1.1 | -1 | -1.24 | -1.09 | -1.17 | -1.11 | -1.21 | 1.73 | -1.22 | -1.08 |
| Estimated EPS | -1.01 | -1.01 | -1.01 | -1.09 | -1.17 | -1.2158 | -1.18 | -1.12 | -1.39 | -1.01 | -1.27 | -1.38 |
| Surprise | 0.1 | 3.34 | -0.09 | 0.09 | -0.07 | 0.1258 | 0.01 | 0.01 | 0.18 | 2.74 | 0.05 | 0.3 |
| Surprise Percentage | 9.901% | 330.6931% | -8.9109% | 8.2569% | -5.9829% | 10.3471% | 0.8475% | 0.8929% | 12.9496% | 271.2871% | 3.937% | 21.7391% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BEAM
2026-05-30 19:39:07
Beam Therapeutics (BEAM) has gained attention following updated Phase 1/2 BEAM-302 trial data for alpha-1 antitrypsin deficiency, showing positive safety and durability signals. Despite recent stock momentum, the company's valuation is a subject of debate, with a narrative estimating fair value at $150 against a current sales multiple suggesting overvaluation. Investors are encouraged to assess the inherent risks and rewards before making investment decisions.
2026-05-28 13:10:36
The article announces that an anti-aging cell therapy has achieved a significant GMP (Good Manufacturing Practice) milestone, indicating progress in its development. This achievement comes amidst a growing number of clinical advancements in the field. The piece highlights the ongoing momentum in anti-aging research and development.
2026-05-28 03:10:03
Beam Therapeutics (BEAM) stock surged 17.6% after the company announced plans to seek accelerated approval for its drug BEAM-302, designed to treat alpha-1 antitrypsin deficiency (AATD). The drug's base-editing approach addresses both liver and lung manifestations of AATD, with updated Phase 1/2 data showing detailed safety, durability, and human neutrophil elastase findings. This development strengthens Beam Therapeutics' investment narrative, potentially establishing BEAM-302 as a significant value driver alongside its other therapeutic programs.
2026-05-27 20:10:36
The article highlights Beam Therapeutics' base editing platform as a "molecular pencil," offering a safer and more precise alternative to traditional CRISPR "molecular scissors" for genetic medicine. It details the success of BEAM-302 for AATD and the potential of the ESCAPE platform to revolutionize gene therapy by eliminating pre-transplant chemotherapy. The author also provides a valuation estimate for Beam of $65 per share, based on an rNPV model of its lead assets, with significant upside potential not yet priced in.
2026-05-27 18:10:03
Beam Therapeutics (BEAM) saw a 13.1% stock increase after announcing plans to seek accelerated FDA approval for BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency. The company aims to restore physiologic alpha-1 antitrypsin responses and plans to expand its pivotal trial. This move highlights Beam's strategy to translate its base-editing platform into revenue-generating therapies, supported by significant capital and existing pipeline programs.
2026-05-26 17:36:13
Beam Therapeutics announced encouraging Phase 1/2 clinical data for BEAM-302 in alpha-1 antitrypsin deficiency and plans to pursue an accelerated approval pathway. This strategy positions BEAM-302 as a critical program, concentrating more of Beam's value on its success alongside sickle cell disease. Investors will closely watch upcoming detailed data, pivotal cohort design, and how the company manages its financial runway and competitive landscape against other gene-editing firms.
